Kimer Med is a biotech start-up, located in Nelson, New Zealand. We are developing a new broad-spectrum antiviral drug. The compound is a derivative of DRACO, which was tested and found effective in vitro against 15 different viruses, and against Influenza H1N1 in mice.

We successfully closed our seed funding round in March 2021, which will allow us extend testing to SARS-CoV-2 and other viruses, and to work toward eventual clinical trials.